Abstract

Salmeterol is a long-acting β₂ adrenoceptor agonist for inhalation which was introduced last December (Serevent - Allen & Hanburys/ Glaxo). In a preliminary review we concluded that it seemed useful for asthmatics who have symptoms despite conventional treatment including full prophylaxis.¹ This article discusses Glaxo’s nationwide surveillance study of salmeterol² which raises some important issues.